scholarly journals Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients

Vaccine ◽  
2020 ◽  
Vol 38 (17) ◽  
pp. 3339-3350 ◽  
Author(s):  
Simon Oesterreich ◽  
Monika Lindemann ◽  
David Goldblatt ◽  
Peter A. Horn ◽  
Benjamin Wilde ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Seroprevalence of SARS-CoV-2 IgG Antibodies After the Second BNT162b2 mRNA Vaccine in Japanese Kidney Transplant Recipients

2021 ◽  
Author(s):  
Tomoko Hamaya ◽  
Shingo Hatakeyama ◽  
Tohru Yoneyama ◽  
Yuki Tobisawa ◽  
Hirotake Kodama ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Neutralizing Antibodies ◽  
Humoral Response ◽  
Healthy Controls ◽  
Transplant Recipients ◽  
Igg Antibodies ◽  
Kidney Transplant Recipients ◽  
Univariate Logistic Regression Analysis ◽  
Antibody Titers

Abstract We aimed to evaluate the rate of anti–SARS-CoV-2 IgG seropositivity and investigated factors associated with seropositivity after the second SARS-CoV-2 mRNA vaccination in kidney transplant (KT) recipients. This retrospective study conducted between June 2021 and November 2021 included 106 KT recipients and 127 healthy controls who received the second dose of the BNT162b2 mRNA vaccine at least seven days before the measurement of antibody titers. The titers of immunoglobulin G (IgG) antibodies against the receptor-binding domain of SARS-CoV-2 spike (S) protein were determined. Seropositivity was defined as an anti–SARS-CoV-2 IgG level of ≥15 units/mL, which was considered as the presence of sufficient neutralizing antibodies. The median ages and the seroprevalence rates of the healthy controls and KT recipients were 68 and 56 years and 98% and 22%, respectively. Univariate logistic regression analysis revealed that age >53 years, rituximab use, mycophenolate mofetil use, and KT vintage <7 years were negatively associated with anti–SARS-CoV-2 IgG seropositivity in KT recipients. Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients. Older age, rituximab use, mycophenolate mofetil use, and KT vintage may play key roles in seroconversion.

scholarly journals Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

2021 ◽  
pp. ASN.2021040490
Author(s):  
Clément Danthu ◽  
Sébastien Hantz ◽  
Arthur Dahlem ◽  
Marion Duval ◽  
Bacary Ba ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Humoral Response ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccination ◽  
Serological Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Medical File ◽  
Hbv Vaccine ◽  
Antibody Titers

Background Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion following vaccination are lower among patients with chronic kidney disease and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. Methods This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36 and 58 days after the first injection. Results In controls, we detected antibodies at a positive level (>13 arbitrary units per milliliter [AU/ml]) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml [IQR, 83.4-526.0]. We detected a positive antibody level in only three transplant recipients at day 36. In hemodialysis patients, those younger than 75 years had a higher antibody response versus those older than 75 years and serum albumin and Kt/V were positively correlated with serological response (P< 0.043 and P<0.019, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers. Conclusions Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients and is reduced by the uremic condition in patients undergoing hemodialysis.

scholarly journals Real-world Effectiveness of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients

2021 ◽  
Author(s):  
Caitriona M. McEvoy ◽  
Anna Lee ◽  
Paraish S. Misra ◽  
Gerald Lebovic ◽  
Ron Wald ◽  
...  
Keyword(s):  
Cohort Study ◽  
Kidney Transplant ◽  
Real World ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
The Real ◽  
Transplant Program ◽  
The Impact

The humoral response to two doses of SARS-CoV-2 (Covid-19) vaccine among transplant recipients is inferior to immunocompetent individuals. Data on the real-world effectiveness of vaccination in kidney transplant recipients [KTRs] are lacking. We performed a cohort study to investigate the impact of vaccination on Covid-19 infection and outcomes in our kidney transplant program.

scholarly journals Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2. The COViNEPH Project

2021 ◽  
Author(s):  
Alicja Dębska-Ślizień ◽  
Marta Muchlado ◽  
Zuzanna Ślizień ◽  
Alicja Kubanek ◽  
Magdalena Piotrowska ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Humoral Response ◽  
Prior Exposure ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals The 5-months impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients

2021 ◽  
Author(s):  
Iddo Z. Ben-Dov ◽  
Yonatan Oster ◽  
Keren Tzukert ◽  
Talia Alster ◽  
Raneem Bader ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Dialysis Patients ◽  
Transplant Patients ◽  
Vitamin D Levels ◽  
Kidney Transplant Patients ◽  
Inhibitor Drug

Background: Determining the humoral immunogenicity of tozinameran (BNT162b2) vaccine in patients requiring chronic renal replacement therapy, and its impact on COVID-19 morbidity several months after vaccination, will guide risk assessment and subsequent changes in vaccination policy. Methods: In a prospective post-vaccination cohort study with up to 5 months follow-up we studied outpatient dialysis and kidney transplant patients and respective healthcare teams. Outcomes were anti S1/S2 antibody response to vaccine or infection and infection rate during followup. Results: 175 dialysis patients (40% women, 65+/-15 years), 252 kidney transplant patients (33% women, 54+/-14 years) and 71 controls (65% women, 44+/-14 years) were followed. Three months or longer after vaccination we detected anti S1/S2 IgG antibodies in 80% of dialysis patients, 44% of transplant recipients and 100% of controls, whereas respective rates after infection were 94%, 75% and 100%. Predictors of non-response were age, diabetes, history of cancer, lower lymphocyte count and lower vitamin-D levels. Factors associated with lower titers in dialysis patients were modality (hemodialysis vs peritoneal) and serum ferritin levels. In transplant patients, hypertension and higher calcineurin or mTOR inhibitor drug levels were linked with diminished antibody response. Vaccination associated with fewer subsequent infections (HR=0.23, p<0.05). Moreover, higher antibody titers associated with fewer events, HR 0.41 for each unit increased in log10titer (p<0.05). Conclusions: Dialysis patients, and more so kidney transplant recipients, mounted delayed and reduced antibody response to COVID-19 mRNA vaccination, and lesser humoral response associated with more infections. Measures to identify and protect non-responsive patients are urgently required.

Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.

1998 ◽  
Vol 9 (8) ◽  
pp. 1521-1525
Author(s):  
N Broeders ◽  
K M Wissing ◽  
A Crusiaux ◽  
P Kinnaert ◽  
P Vereerstraeten ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Humoral Response ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Levels ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Serum Samples ◽  
The Impact

OKT3 monoclonal antibody, a murine IgG2a monoclonal antibody targeting the T cell CD3 antigen, elicits a neutralizing humoral response in 20 to 50% of kidney transplant recipients when the concomitant immunosuppression consists of CsA-Sandimmun (SAND) and azathioprine (AZA). In the present study, we investigated the impact of the newer agents, CsA-Neoral (NEO) and mycophenolate mofetil (MMF) on OKT3 sensitization. Sixty-two consecutive kidney transplant recipients received prophylactic OKT3 (5 mg/d) from days 0 to 13, together with steroids. Concomitant immunosuppression consisted of either AZA + SAND (n=20), AZA + NEO (n=31), or MMF + NEO (n=11). The following doses were used: AZA, 2 mg/kg per d from days 0 to 13, then 1 mg/kg per d; MMF, 2 g/d starting on day 1; and CsA, either SAND or NEO, 6 mg/kg per d from day 6. At least two serum samples per month were available during the initial 3 mo for each patient. IgG anti-OKT3 antibodies were first evaluated by enzyme-linked immunosorbent assay. Patients were considered sensitized if their serum scored positive at a dilution > or = 1/1000. Peak titers of IgG anti-OKT3 antibodies and the incidence of patients harboring neutralizing anti-idiotypic antibodies were also determined. A first reduction in OKT3 sensitization was seen in patients receiving Neoral instead of Sandimmun (AZA + SAND: 10 of 20 [50%] patients sensitized versus 6 of 31 [19%] in the AZA + NEO group; P=0.03). This was probably related to the achievement of higher mean CsA trough blood levels in the NEO group during the first month (253+/-44 versus 186+/-49 ng/ml in SAND patients). Peak antibody titers and the proportion of patients with anti-idiotypic antibodies were similar in the AZA + SAND and AZA + NEO groups. A further reduction in the sensitization rate was observed with the replacement of AZA by MMF (MMF + NEO: 0% sensitized patients; P=0.0013). It is concluded that the combination of CsA-Neoral and MMF efficiently prevents sensitization against OKT3.

scholarly journals Cellular and humoral response after mRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients

2021 ◽  
Author(s):  
David Cucchiari ◽  
Natalia Egri ◽  
Marta Bodro ◽  
Sabina Herrera ◽  
Jimena Del Risco‐Zevallos ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS‐CoV‐2 vaccine

2021 ◽  
Author(s):  
Ayelet Grupper ◽  
Eugene Katchman ◽  
Merav Ben‐Yehoyada ◽  
Liane Rabinowich ◽  
Doron Schwartz ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1165
Author(s):  
Alicja Dębska-Ślizień ◽  
Zuzanna Ślizień ◽  
Marta Muchlado ◽  
Alicja Kubanek ◽  
Magdalena Piotrowska ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Seroconversion Rate ◽  
Booster Vaccination ◽  
Humoral Response ◽  
Transplant Recipients ◽  
Igg Antibodies ◽  
Kidney Transplant Recipients ◽  
Younger Age ◽  
Subgroup Analyses ◽  
Immunosuppressive Protocol

Background: The efficacy of SARS-CoV-2 vaccination among kidney transplant recipients (KTR) is low. The main goal of this study was to analyze factors that may influence the humoral response to vaccination. Methods: We analyzed the titer magnitude of IgG antibodies directed against spike (S)-SARS-CoV-2 antigen after the second dose of the mRNA vaccine in 142 infection naïve KTR (83 men, i.e., 58.4%) with a median age (IQR) of 54 (41–63), and 36 respective controls without chronic kidney disease. mRNA-1273 or BNT162b2 were applied in 26% and 74% of KTR, respectively. Results: S-specific immune response (seroconversion) was seen in 73 (51.41%) of KTR, and in all controls 36 (100%). Independent predictors of no response were elder age, shorter transplantation vintage, and a more than two-drug immunosuppressive protocol. In subgroup analyses, the seroconversion rate was highest among KTR without MMF/MPS treatment (70%), treated with no more than two immunosuppressants (69.2%), treated without corticosteroid (66.7%), younger patients aged <54 years (63.2%), and those vaccinated with the mRNA-1273 vaccine (62.16%). The independent predictors of higher S-antibody titer among responders were younger age, treatment with no more than two immunosuppressants, and the mRNA-1273 vaccination. Conclusions: Our study confirmed a low rate of seroconversion after vaccination with the mRNA vaccine in KTR. The major modifiable determinants of humoral response were the composition of the immunosuppressive protocol, as well as the type of vaccine. The latter could be taken into consideration when initial vaccination as well as booster vaccination is considered in KTR.

Sign in / Sign up

Export Citation Format

Share Document